Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus

Marissa C. Blank; Radu N. Stefanescu; Emi Masuda; Francesc Marti; Philip D. King; Patricia B. Redecha; Robert J. Wurzburger; Margaret G.E. Peterson; Shizuko Tanaka; Luminita Pricop

doi:10.1007/s00439-005-1302-3

Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus

Marissa C. Blank, Radu N. Stefanescu, Emi Masuda, Francesc Marti, Philip D. King, Patricia B. Redecha, Robert J. Wurzburger, Margaret G.E. Peterson, Shizuko Tanaka, Luminita Pricop

Surgery

Research output: Contribution to journal › Article › peer-review

143 Scopus citations

Abstract

The role for inhibitory Fc gamma receptors class IIb (FcγRIIb) in the onset, progression and severity of several animal models of autoimmune diseases is well established. By contrast, the pathogenic potential of FcγRIIb in human autoimmune diseases remains largely unknown. Here we report the identification of a polymorphism in the human FCGR2B promoter (dbSNP no. rs3219018) that is associated in homozygosity with systemic lupus erythematosus (SLE) phenotype in European-Americans (OR=11.1, P=0.003). Experimental evidence correlates the polymorphism (a G-C substitution at position -343 relative to the start of transcription) with altered FcγRIIb expression and function. The G-C substitution correlated with decreased transcription of the FCGR2B promoter, and resulted in decreased binding of the AP1 transcription complex to the mutant promoter sequence. The surface expression of FcγRIIb receptors was significantly reduced in activated B cells from (-343 C/C) SLE patients. These findings suggest that genetic defects may lead to deregulated expression of the FCGR2B gene in -343 C/C homozygous subjects, and may play a role in the pathogenesis of human SLE.

Original language	English
Pages (from-to)	220-227
Number of pages	8
Journal	Human Genetics
Volume	117
Issue number	2-3
DOIs	https://doi.org/10.1007/s00439-005-1302-3
State	Published - Jul 2005

Bibliographical note

Funding Information:
Acknowledgements We thank Jane Salmon and Heidi Norbis for providing blood and DNA samples from the HSS Autoimmune Registry and Repository, and Francesco Ramirez for reviewing the manuscript. This work was supported by grants from the National Institutes of Health AR49765, the SLE Foundation, the Mary Kirkland Lupus Center and the Arthritis Foundation (to L. Pri-cop). This investigation was conducted in a facility constructed with support from Research Facilities Improvement Program Grant Number C06-RR12538-01 from the National Center for Research Resources, National Institutes of Health.

Keywords

FCGR2B
ITIM
Systemic lupus erythematosus
Transcriptional regulation

ASJC Scopus subject areas

Genetics
Genetics(clinical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00439-005-1302-3

Cite this

Blank, M. C., Stefanescu, R. N., Masuda, E., Marti, F., King, P. D., Redecha, P. B., Wurzburger, R. J., Peterson, M. G. E., Tanaka, S., & Pricop, L. (2005). Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus. Human Genetics, 117(2-3), 220-227. https://doi.org/10.1007/s00439-005-1302-3

@article{871724e46338440aacbeb64e7c97e281,

title = "Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus",

abstract = "The role for inhibitory Fc gamma receptors class IIb (FcγRIIb) in the onset, progression and severity of several animal models of autoimmune diseases is well established. By contrast, the pathogenic potential of FcγRIIb in human autoimmune diseases remains largely unknown. Here we report the identification of a polymorphism in the human FCGR2B promoter (dbSNP no. rs3219018) that is associated in homozygosity with systemic lupus erythematosus (SLE) phenotype in European-Americans (OR=11.1, P=0.003). Experimental evidence correlates the polymorphism (a G-C substitution at position -343 relative to the start of transcription) with altered FcγRIIb expression and function. The G-C substitution correlated with decreased transcription of the FCGR2B promoter, and resulted in decreased binding of the AP1 transcription complex to the mutant promoter sequence. The surface expression of FcγRIIb receptors was significantly reduced in activated B cells from (-343 C/C) SLE patients. These findings suggest that genetic defects may lead to deregulated expression of the FCGR2B gene in -343 C/C homozygous subjects, and may play a role in the pathogenesis of human SLE.",

keywords = "FCGR2B, ITIM, Systemic lupus erythematosus, Transcriptional regulation",

author = "Blank, {Marissa C.} and Stefanescu, {Radu N.} and Emi Masuda and Francesc Marti and King, {Philip D.} and Redecha, {Patricia B.} and Wurzburger, {Robert J.} and Peterson, {Margaret G.E.} and Shizuko Tanaka and Luminita Pricop",

note = "Funding Information: Acknowledgements We thank Jane Salmon and Heidi Norbis for providing blood and DNA samples from the HSS Autoimmune Registry and Repository, and Francesco Ramirez for reviewing the manuscript. This work was supported by grants from the National Institutes of Health AR49765, the SLE Foundation, the Mary Kirkland Lupus Center and the Arthritis Foundation (to L. Pri-cop). This investigation was conducted in a facility constructed with support from Research Facilities Improvement Program Grant Number C06-RR12538-01 from the National Center for Research Resources, National Institutes of Health.",

year = "2005",

month = jul,

doi = "10.1007/s00439-005-1302-3",

language = "English",

volume = "117",

pages = "220--227",

number = "2-3",

}

TY - JOUR

T1 - Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus

AU - Blank, Marissa C.

AU - Stefanescu, Radu N.

AU - Masuda, Emi

AU - Marti, Francesc

AU - King, Philip D.

AU - Redecha, Patricia B.

AU - Wurzburger, Robert J.

AU - Peterson, Margaret G.E.

AU - Tanaka, Shizuko

AU - Pricop, Luminita

N1 - Funding Information: Acknowledgements We thank Jane Salmon and Heidi Norbis for providing blood and DNA samples from the HSS Autoimmune Registry and Repository, and Francesco Ramirez for reviewing the manuscript. This work was supported by grants from the National Institutes of Health AR49765, the SLE Foundation, the Mary Kirkland Lupus Center and the Arthritis Foundation (to L. Pri-cop). This investigation was conducted in a facility constructed with support from Research Facilities Improvement Program Grant Number C06-RR12538-01 from the National Center for Research Resources, National Institutes of Health.

PY - 2005/7

Y1 - 2005/7

N2 - The role for inhibitory Fc gamma receptors class IIb (FcγRIIb) in the onset, progression and severity of several animal models of autoimmune diseases is well established. By contrast, the pathogenic potential of FcγRIIb in human autoimmune diseases remains largely unknown. Here we report the identification of a polymorphism in the human FCGR2B promoter (dbSNP no. rs3219018) that is associated in homozygosity with systemic lupus erythematosus (SLE) phenotype in European-Americans (OR=11.1, P=0.003). Experimental evidence correlates the polymorphism (a G-C substitution at position -343 relative to the start of transcription) with altered FcγRIIb expression and function. The G-C substitution correlated with decreased transcription of the FCGR2B promoter, and resulted in decreased binding of the AP1 transcription complex to the mutant promoter sequence. The surface expression of FcγRIIb receptors was significantly reduced in activated B cells from (-343 C/C) SLE patients. These findings suggest that genetic defects may lead to deregulated expression of the FCGR2B gene in -343 C/C homozygous subjects, and may play a role in the pathogenesis of human SLE.

AB - The role for inhibitory Fc gamma receptors class IIb (FcγRIIb) in the onset, progression and severity of several animal models of autoimmune diseases is well established. By contrast, the pathogenic potential of FcγRIIb in human autoimmune diseases remains largely unknown. Here we report the identification of a polymorphism in the human FCGR2B promoter (dbSNP no. rs3219018) that is associated in homozygosity with systemic lupus erythematosus (SLE) phenotype in European-Americans (OR=11.1, P=0.003). Experimental evidence correlates the polymorphism (a G-C substitution at position -343 relative to the start of transcription) with altered FcγRIIb expression and function. The G-C substitution correlated with decreased transcription of the FCGR2B promoter, and resulted in decreased binding of the AP1 transcription complex to the mutant promoter sequence. The surface expression of FcγRIIb receptors was significantly reduced in activated B cells from (-343 C/C) SLE patients. These findings suggest that genetic defects may lead to deregulated expression of the FCGR2B gene in -343 C/C homozygous subjects, and may play a role in the pathogenesis of human SLE.

KW - FCGR2B

KW - ITIM

KW - Systemic lupus erythematosus

KW - Transcriptional regulation

UR - http://www.scopus.com/inward/record.url?scp=26944456633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26944456633&partnerID=8YFLogxK

U2 - 10.1007/s00439-005-1302-3

DO - 10.1007/s00439-005-1302-3

M3 - Article

C2 - 15895258

AN - SCOPUS:26944456633

SN - 0340-6717

VL - 117

SP - 220

EP - 227

JO - Human Genetics

JF - Human Genetics

IS - 2-3

ER -

Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this